Leadership

Prior to joining Neuronetics, Mr. Sullivan had most recently served as Chief Commercial Officer and President (North America) of ZELTIQ Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting® brand, from January 2016 until the acquisition of ZELTIQ by Allergan, Inc. in April 2017. Mr. Sullivan previously served as Senior Vice President and Chief Commercial Officer of ZELTIQ from November 2014 until January 2016 and as Senior Vice President of Worldwide Sales and Marketing from July 2013 through October 2014.

Mr. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic, Vision Quest Laser Center and Coherent Medical.

Mr. Sullivan received a Bachelor of Business Administration from the College of William and Mary and is a clinical professor in the Mason School of Business at William and Mary. Mr. Sullivan currently serves on the Board of Directors of Venus Concept and Cutera and formerly served on the Board of Directors of Sientra.

Cory Anderson joins Neuronetics with over 20 years of medical technology experience, along with deep executive leadership within medical device startup companies.

Most recently, Mr. Anderson served as Vice President, Business Development and Marketing (Corporate Officer) at Sebacia. During his time at Sebacia, he led phase IV clinical trials in five countries and strategically guided the company’s R&D pipeline. Prior to Sebacia, he was VP Business Development at The Innovation Factory (TIF, the incubator where Neuronetics started) and a Principal at Accuitive Medical Ventures (AMV, venture investor in Neuronetics). During his time at TIF and AMV, Mr. Anderson managed operations of two portfolio companies in the ophthalmic space, evaluated new business/investment opportunities, and supported investments in the portfolio of companies.

Prior to his time at TIF and AMV, Mr. Anderson held positions of increasing responsibility within Product Development and Marketing at Novoste Corporation where he developed products for interventional cardiology.

Mr. Anderson has been a board observer and investor in two successful exits of venture-backed companies: AqueSys (acquired by Allergan/AbbVie, NYSE: ABBV) and MyoScience (acquired by Pacira BioSciences, NASDAQ: PCRX).

Mr. Anderson holds Bachelor’s and Master’s degrees in Biomedical Engineering from Tulane University, and an MBA from Emory University. Mr. Anderson is an inventor on seven issued US patents and an author of two peer-reviewed papers and one book chapter.

Steve Furlong has been part of the Neuronetics leadership team since July 2019. Prior to joining the company, Mr. Furlong worked at Metabolon, a private life science company in metabolomics, a phenotyping technology for advancing biomarker discovery, diagnostic testing and precision medicine, from November 2017 to July 2019, where he most recently served as Senior Vice President of Finance and Corporate Secretary.
Prior to joining Metabolon, Mr. Furlong was Vice President Finance at Verscend Technologies from February 2017 to June 2017. From April 2015 to September 2016, Mr. Furlong served as Chief Financial Officer of Rapid Micro Biosystems, which manufactures and distributes products for detection of microbial contamination. Before joining Rapid Micro Biosystems, Mr. Furlong spent 14 years at Hologic, a publicly-traded medical technology company, where he held a number of roles of increasing responsibilities, most recently Senior Vice President, Finance and Sales Administration.
Prior to his experience at Hologic, Mr. Furlong held positions at Safety 1st, Stratus Computer Inc., and Raytheon Company. Mr. Furlong received his B.A. in Political Science from The Pennsylvania State University and his Master of Finance degree from Bentley University.

Rick Grubbs comes to Neuronetics with over 30 years of experience in sales and management. Prior to joining Neuronetics, his previous eight years were spent as Director of Sales with Allergan Aesthetics (formerly ZELTIQ), commercializing and growing the CoolSculpting brand.

Mr. Grubbs’ previous sales and management experience includes roles at Lumenis, Lutronic and Solta Medical, among other medical device and pharmaceutical companies. He earned his Bachelor of Arts degree in Communications from California State University, Fullerton.

Sara Grubbs brings 20 years of sales and management experience to Neuronetics and has spent the past 15 years successfully commercializing medical devices with a consumable component similar to NeuroStar®. She previously served in sales leadership and management roles with Revance Aesthetics, Allergan (formerly ZELTIQ), Ulthera, and Solta Medical as well as other medical device and pharmaceutical companies. Sara received her Bachelor of Science degree in Business and Entrepreneurship from the University of Southern California.

W. Andrew Macan has been with Neuronetics since January 2020.

Prior to joining Neuronetics, Mr. Macan was Senior Vice President, General Counsel and Corporate Secretary of U.S. Silica Holdings, Inc., a Russell 2000 diversified minerals company, from October 2018 until January 2020. He served in roles of increasing responsibility with Axalta Coating Systems, LLC, from October 2013 until October 2018, most recently as General Counsel and Chief Compliance Officer, Americas, and The Chubb Corporation, from October 2003 until October 2013, including as Vice President, Corporate Counsel and Secretary for over 8 years.

Mr. Macan began his career in private practice at Ballard Spahr LLP and Dechert LLP. He earned a B.A. in Government from Franklin & Marshall College and his J.D. from Emory University School of Law with distinction and Order of the Coif.

Lisa Metzner-Rosas brings over 20 years of marketing leadership in a wide range of medical device and pharmaceutical businesses.

Prior to joining Neuronetics, Ms. Metzner-Rosas was the Senior Vice President of Marketing at Sientra, where she championed the global commercial strategy, leading to 10 consecutive quarters of record high sales while tripling market share.

Previous to Sientra, she held the position of Vice President of Marketing at Obalon Therapeutics, which went public in 2016, and ZELTIQ Aesthetics, where she played a critical role in establishing category superiority for the CoolSculpting brand prior to the acquisition by Allergan in 2017. She has also held leadership positions at Medicis and Allergan previously.

Ms. Metzner-Rosas has been awarded a BA in Communication from the University of Wisconsin and an MBA from Graziadio School of Business and Management, Pepperdine University. She has also done graduate work at the University Adolfo Ibanez in Chile as well as the University of Oxford in England.

Rusty Page joins Neuronetics with over 20 years of medical device experience. He brings vast expertise through his career working with multiple medical device companies in leadership roles spanning Operations, Quality, and Information Technology Systems.

Notably, Mr. Page was a founding member of Bioness, Inc., a leading provider of innovative medical devices specializing in neuro-rehabilitation and implantable products for pain management. At Bioness, his most recent positions were Vice President of Operations and Quality, while concurrently serving as General Manager of Bioness Israel.

Mr. Page brings extensive experience in executive leadership, global operations, Information Technology and Quality Management Systems. Mr. Page earned his Bachelor of Arts in Organizational Management from Master’s University.

Robert A. Cascella joined the Neuronetics Board of Directors in April 2021. He has more than 30 years of experience in the healthcare industry in a range of senior management positions and has served on several boards.

Mr. Cascella joined Philips in 2015 and is currently a Special Advisor to the Company. Prior to this advisory role, he held the position of Executive Vice President and Strategic Business Development Leader at Royal Philips and was also a member of the company’s Executive Committee. Mr. Cascella has held several other leadership roles at Philips, including Chief Business Leader for the Precision Diagnosis Segment and Chief Business Leader of the Diagnosis and Treatment Segment. Over this period, Mr. Cascella was responsible for the turnaround of multiple lines of business and the completion of several strategic acquisitions.

Prior to Philips, Mr. Cascella spent ten years as President and later CEO of Hologic Inc., a global leader in women’s health. Over this period, Hologic grew from a $180 million capital equipment business to a $2.5 billion leader in women’s health.

Earlier in his career Mr. Cascella was a partner and executive committee member of CFG Capital, a boutique investment bank, where he represented the firm’s healthcare business. Over his career he has held various senior management positions ranging from CFO and VP Finance to President and COO for NeoVision, a breast ultrasound start-up company sold to US Surgical and Fischer Imaging.

Mr. Cascella has led or participated in over 15 acquisitions at an aggregate deal value of over $12 billion and has raised over $3 billion in debt and equity over his career. He holds a BA from Fairfield University. Currently he is on the Boards of Celestica (CLS: NYSE) a Canadian contract manufacturer and Metabolon a private company focused on the use of metabolomics for improved disease characterization.

Avinash Amin, MD, has served as the Managing Partner of Madryn Asset Management, LP, a leading alternative asset management firm that invests in innovative healthcare companies, since 2017. Prior to forming Madryn Asset Management, LP, Dr. Amin was a Partner at Visium Fund Management, LP, an investment management firm, where he was the head of the fund’s New York office and was responsible for structured debt, growth equity, and royalty investments in the healthcare industry, from 2014 through 2017. From 2009 through 2014, Dr. Amin was a Managing Director at Siguler Guff & Company, LP, a multi-strategy private equity firm. At Siguler Guff & Company, LP, Dr. Amin headed the firm’s healthcare investment strategy and was responsible for sourcing and leading healthcare investments including royalty monetizations, specialty financings, and buyout/growth equity transactions in both developed and emerging economies. Prior to Siguler Guff & Company, LP, Dr. Amin headed the private equity advisory business of Summit Strategies Group. Prior to joining the financial services industry, Dr. Amin served as the Vice President, Chief Clinical Officer at Novactyl, Inc., from 2000 to 2005.

Dr. Amin earned an MD from Washington University in St. Louis, Missouri, where he completed his residency and practiced as a physician, and an MHA and a BA in classics from Washington University in St. Louis. Dr. Amin is board certified in Internal Medicine.

Sheryl Conley brings more than 30 years of leadership experience in the medical device industry. Ms. Conley previously served as the Group President – Americas, Global Brand Management and Chief Marketing Officer at Zimmer Holdings, where she led the company’s largest and most profitable business segments. During her 25-year career at Zimmer, she held a number of escalating management roles across a variety of product segments and geographies, during which she provided key leadership in the development and commercial release of over 50 industry leading brands. She holds a Bachelor of Science in Biology and Chemistry and an MBA from Ball State University in Indiana. Ms. Conley is a member of the Audit committee.

As the CEO of Greybrook Securities Inc. and along with his partners, Sasha is responsible for leading the firm’s capital markets and real estate investment strategies. Under his leadership and on behalf of its L.P.’s in over 30 countries, Greybrook’s portfolio has grown to include over 110 multi-family and residential development projects and over $40 billion worth of estimated completion value. Sasha co-chairs Greybrook’s Investment and Project Advisory Committees which are responsible for approving new acquisitions and actively managing all existing project partnerships.

As the former President of Greybrook Health, Sasha also played a key role in several portfolio acquisitions including MacuHealth, Bruder Healthcare and TearLab, as well as the launch of Greenbrook TMS (NASDAQ: GBNH; TSX: GTMS), a leading provider of TMS therapy, an FDA-cleared, non-invasive therapy for the treatment of a major depressive disorder. In 2020, he led the launch of Delos Canada, as well as Greybrook’s investment in Delos Living, LLC a global leader in the health and building sciences.

Glenn P. Muir, a certified public accountant, has extensive experience in finance and financial reporting. Glenn was Hologic’s Chief Financial Officer from 1992 to May 2014 and its only Executive Vice President since 2000 with a broad range of operating responsibilities including the key architect in the formulation and implementation of the Company’s strategic initiatives.
While at Hologic for over 25 years Glenn was at the helm of the Company’s IPO in 1990 when it was a single-product single-disease niche medical product company and continuing to the leader it is today in women’s health. Hologic has grown and evolved to a provider of advanced technologies that make a difference in people’s lives with operations around the world, revenues of over $2.5 billion, an enterprise value exceeding $10 billion and over 6,000 employees.
Glenn has steered two companies through IPO’s (and numerous follow-on offerings), built world-class organizations, raised over $5 billion in debt and led the acquisition/integration of over twenty companies. His industry experience is specific to the healthcare industry and includes medical imaging, diagnostics and surgical solutions.
Currently a member of the Board of Directors and the Audit Committee Chair at Repligen Corporation (Nasdaq: RGEN – http://www.repligen.com/), ReWalk Robotics Ltd (Nasdaq: RWLK – http://rewalk.com/) and G1 Therapeutics, Inc. (http://www.g1therapeutics.com/). His past Board of Director experience also includes RainDance Technologies, Inc. from 2014 until its acquisition by Bio-Rad Laboratories in February 2017, Hologic, Inc. (Nasdaq: HOLX) from 2001 to 2013 and Vivid Technologies, Inc. (Nasdaq: VVID) from 1996 until the Company was sold to EG&G in 1999.
Glenn graduated from the University of Massachusetts in Amherst where he was Treasurer and Board Member of the UMass Student Federal Credit Union. He has two graduate degrees: a Master in Business Administration from Harvard University Graduate School of Business Administration (full-time) and a Master in Science in Taxation from Bentley College Graduate School of Business (part-time).
One of 2009 America’s Best CFOs as surveyed by Institutional Investor. Boston Business Journals 2011 CFO of the year.
Member of the American Institute of Certified Public Accountants and the Massachusetts Society of Certified Public Accountants.
Glenn lives in Lexington, Massachusetts with his wife and three children. With his family he enjoys the BVI, skiing, bridge and the Boy Scouts. His contact information is: glennmuir@outlook.com; Cell: (617) 633-2276.

Megan Rosengarten joined the Neuronetics Board of Directors in August 2021. Ms. Rosengarten is a proven leader known for commercializing new insights and opportunities, resulting in sustainable growth and iconic Brands. She has broad experience across the medical device and consumer product industries, spanning over two decades of marketing and strategic leadership.

Ms. Rosengarten serves as President of Surgical Robotics at Medtronic, where she led the launch of a new robotics business and integration of an acquired medical training and AI start-up.

Prior to joining Medtronic, she served as the VP, Global Marketing for Hologic’s Breast and Skeletal Health Division where she served a key role in accelerating growth through product innovation and brand building. In addition, she has held a variety of roles in product management, marketing, and strategy at Covidien and Johnson & Johnson.

Ms. Rosengarten earned her M.B.A. from Kenan-Flagler Business School at UNC, with concentrations in marketing and international business, and her B.S. in Biological Anthropology and Anatomy from Duke University.

Prior to joining Neuronetics, Mr. Sullivan had most recently served as Chief Commercial Officer and President (North America) of ZELTIQ Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting® brand, from January 2016 until the acquisition of ZELTIQ by Allergan, Inc. in April 2017. Mr. Sullivan previously served as Senior Vice President and Chief Commercial Officer of ZELTIQ from November 2014 until January 2016 and as Senior Vice President of Worldwide Sales and Marketing from July 2013 through October 2014.

Mr. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic, Vision Quest Laser Center and Coherent Medical.

Mr. Sullivan received a Bachelor of Business Administration from the College of William and Mary and is a clinical professor in the Mason School of Business at William and Mary. Mr. Sullivan currently serves on the Board of Directors of Venus Concept and Cutera and formerly served on the Board of Directors of Sientra.